Search results
26 sie 2021 · As a result, the presence of malignant ascites in advanced-stage ovarian cancer patients is associated with a poor prognosis, warranting the development of more effective treatments for the palliation of malignant ascites.
The management of malignant ascites in ovarian cancer consists of both limiting the development of peritoneal fluid accumulation and addressing its outflow. As therapies for recurrent disease rarely lead to a cure, the therapeutic intent should focus on improving QOL.
8 maj 2020 · The most important factor that influences patient prognosis in ovarian cancer is the resectability of the primary tumour and metastatic deposits—survival is optimal in cases where...
7 lip 2020 · The most important factor that influences patient prognosis in ovarian cancer is the resectability of the primary tumour and metastatic deposits—survival is optimal in cases where the cancer is optimally debulked. 18–20 Ascites has been shown to increase the chance of suboptimal cytoreduction and is significantly associated with shorter ...
26 sie 2021 · Treatment options for malignant ascites, including surgical, pharmacological and photochemical interventions are then discussed to highlight challenges and opportunities at the interface of drug discovery, device development and physical sciences in oncology.
21 lut 2013 · One study has suggested that ascites at presentation is an independent prognostic factor for time to relapse 6 and, overall, more than one-third of women with ovarian cancer develop ascites...
Malignant ascites is one of the most common sequela of epithelial ovarian cancer. It causes significant symptoms and can have a detrimental impact on patient quality of life, especially in women with recurrent ovarian cancer.
